When was SignaCor founded?

SignaCor was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is SignaCor located?

SignaCor is headquartered in Belfast, United Kingdom.

Who is the current CEO of SignaCor?

Chris Watson of SignaCor. They have also founded 1 company.

How many employees does SignaCor have?

As of Jul 31, 2026, the latest employee count at SignaCor is 3.

Is SignaCor a funded company?

SignaCor is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 10, 2026.

When was the latest funding round of SignaCor?

SignaCor's latest funding was a $***** Seed round on Mar 10, 2026, with participation from 1 investor. Its primary sector is Cardiac and Vascular Disorders. Globally, the Cardiac and Vascular Disorders sector has seen $1.49B in funding in 2026 to date.

Where does SignaCor rank among its competitors?

SignaCor ranks 244th amongst 368 active competitors, of which 110 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Rejuvenate Bio, which secured $19.5M in Jun, 2026.

Who are the top competitors of SignaCor?

SignaCor's top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Rejuvenate Bio secured the most recent funding round in June, 2026.

SignaCor - 2026 Company Profile, Team, Funding & Competitors

SignaCor is a seed company based in Belfast (United Kingdom), founded in 2024 by Chris Watson. It operates as a Developer of therapeutics for cardiac diseases. SignaCor has raised $334K in funding. The company has 368 active competitors, including 110 funded and 105 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.

Company Details

Developer of therapeutics for cardiac diseases. It offers a patented low-dose 5-aza therapy that harnesses DNA methylation to address multiple underlying causes of symptomatic hypertrophic cardiomyopathy including established fibrosis a key driver of disease progression.

Key Metrics

Founded Year

2024

Location

Belfast, United Kingdom

Stage

Seed

Total Funding

$334K in 1 round

Latest Funding Round

Seed, Mar 10, 2026, $*****

Investors

Zinc

Ranked

244^th among 368 active competitors

Employee Count

3 as on Jul 31, 2026

Similar Companies

Tenaya Therapeutics & 347 more

View SignaCor's full profile

SignaCor has raised a total funding of $334K over 1 round. Its latest funding round was a Seed round on Mar 10, 2026 for $*****. 1 investor participated in its latest round. SignaCor has 1 institutional investor.

Here is the list of recent funding rounds of SignaCor:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 10, 2026	7379901	Seed	4213190	3082345	3418088	5469743

Access funding benchmarks and valuations. Sign up today!

View details of SignaCor's funding rounds and investors

The founders of SignaCor is Chris Watson. Chris Watson is the CEO of SignaCor.

Here are the details of SignaCor's key team members:

Chris Watson: Founder & CEO of SignaCor.
Contact Info: 1 email address

View details of SignaCor's Founder profiles and Board Members

SignaCor's employee count trend

SignaCor has 3 employees as of Jul 26. Here is SignaCor's employee count trend over the years:

Uncover SignaCor's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SignaCor include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of SignaCor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	67/100
4th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	66/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Longitude Capital & 16 others	66/100
7th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	8VC, Humboldt Fund & 7 others	65/100
8th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
9th	Rejuvenate Bio 2018, San Diego (United States), Series A	Developer of gene therapies for treating chronic and age-related diseases	$34M	VCapital, Digitalis Ventures & 12 others	62/100
10th	Innovent Bio 2011, Suzhou (China), Public	Developer of antibody therapeutics for multiple diseases	$535M	Eight Roads Ventures, Lilly Asia Ventures ... & 24 others	62/100
244th	SignaCor 2024, Belfast (United Kingdom), Seed	Developer of therapeutics for cardiac diseases	$334K	Zinc	26/100